Taysha Gene Therapies shareholders approve authorized share increase to 700M

Taysha Gene Therapies, Inc.

Authorized common stock increased from 400M to 700M shares; approved 171.3M for, 8.2M against.
Directors Phillip B. Donenberg and Sukumar Nagendran elected with 114.3M and 123.3M votes for, respectively.
Deloitte & Touche ratified as independent auditor for FY2025; 179.4M votes for.
Annual meeting turnout: 179.6M shares (~87%) of 205.1M outstanding represented.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.